Table 6.

Recommended monitoring for the approved oral multiple sclerosis drugs^1,3,4

	Dimethyl fumarate	Fingolimod	Teriflunomide
Bilirubin		Within 6 mo prior to starting therapy	Within 6 mo prior to starting therapy
Blood pressure		Periodically throughout therapy	Prior to start of therapy and periodically throughout therapy
Complete blood cell count	Within 6 mo prior to starting therapy, annually, and as clinically indicated	Within 6 mo prior to starting therapy	Within 6 mo prior to starting therapy
Electrocardiogram		Prior to first dose and at the end of the first dose observation period
Heart rate		During first dose and periodically throughout therapy
Serum potassium			If symptomatic or in patients with acute renal failure
Serum transaminase		Within 6 mo prior to starting therapy	Within 6 mo prior to starting therapy; monitor monthly for 6 mo after starting therapy
Spirometric evaluation		When needed during therapy